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Background: Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application
of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based
on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited
to patients with established disease manifestation. Therefore, for improved disease prevention it is important to
develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into
the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T
cells before clinical aGVHD onset to permit for efficient therapeutic intervention.
Methods: Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen
(miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells
with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood
mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression
profiles.
Results: We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after
miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7
integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with
rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented
lethal aGVHD.
Conclusions: Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to
identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention.
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Allogeneic hematopoietic cell transplantation (allo-HCT)
is the only curative treatment option for many malignant
diseases due to the beneficial immunological graft-versus-
leukemia (GVL) effect [1]. However, (acute) graft-versus-
host disease ((a)GVHD) continues to be a major
complication after allo-HCT. This syndrome is caused by
donor T cells that attack the intestinal tract, liver, and skin
[2]. Early diagnosis remains challenging and to date
mainly relies on clinical symptoms and histopathology.
When clinical symptoms are readily detected, response to
therapy is rarely beneficial to the patient. Therefore, a pre-
dictive test to identify patients at risk before the visible on-
set of aGVHD is highly desirable.
A detailed understanding of the pathophysiological
processes including the kinetics of alloreactive T cell
priming, migration, and effector mechanisms after allo-
HCT may provide clues to identify patients that are
likely to develop aGVHD. Recently, in vivo biolumines-
cence imaging (BLI) of T cells that carried the firefly
luciferase (luc+) gene in a major histocompatibility com-
plex (MHC) mismatched mouse model helped define a
distinct aGVHD initiation and effector phase [3]. Donor
T cells first migrated into secondary lymphoid organs
(SLOs), where they were activated by interacting with
host antigen presenting cells (APCs). This interaction
led to the upregulation of certain homing receptors
which the cells used for target tissue infiltration [3]. The
subsequent effector phase, taking place in peripheral
aGVHD target tissues, started 3 days later when alloreactive
T cells left the SLOs and migrated via the peripheral blood
(PB) to their respective target organs, mainly the gastro-
intestinal tract (GIT), the liver, and the skin [4-6].
In the present work, we asked whether it is possible to
detect alloreactive donor T cells in the PB early after
allo-HCT in a clinically relevant minor histocompatibil-
ity antigen (miHAg) mismatch mouse model. We char-
acterized donor T cells according to the expression of
two well-described homing receptors, α4β7 integrin and
P-selectin ligand. Based on these observations we
succeeded in effectively treating mice with rapamycin on
first alloreactive cell detection in the PB to timely pre-
vent aGVHD exacerbation.
Methods
Ethics statement
All experiments were performed according to the German
regulations for animal experimentation and approved by
the Regierung von Unterfranken as the responsible au-
thority (Permit Number 55.2-2531.01-30/09).
Mice
All HCT experiments were performed with sex-matched
8 to 12-week-old mice. BALB/c (H-2d, CD90.2) andC57Bl/6 (H-2b, CD90.2) mice obtained from Charles
River (Sulzfeld, Germany); BALB/b (H-2b, CD90.2) and
congenic C57Bl/6 (H-2b, CD45.1) obtained from Jackson
Laboratories (Bar Harbor, ME, USA). The luciferase-
expressing (luc+) transgenic FVB-L2G85 line [7] was
backcrossed over 12 generations onto C57Bl/6 (H-2b,
CD90.1) background. Mice were housed in a pathogen-
free facility at the Center for Experimental Molecular
Medicine (ZEMM), Würzburg, Germany.Flow cytometry analysis
Cells were stained with the following antibodies (clones):
anti-CD8α (53-6.7), anti-CD4 (RM4-5), anti-CD90.1 (H1S51),
anti-CD45.1 (A20), anti-LPAM-1/α4β7 (DATK32) from
Biolegend (Uithoorn, The Netherlands) and eBioscience
(Frankfurt, Germany), P-selectin ligand-IgG fusion protein
(Becton Dickinson (BD), Heidelberg, Germany), anti-
human-IgGκ-FITC (Jackson ImmunoResearch Laborator-
ies, West Grove, PA, USA). Dead cells were excluded with
propidium iodide (PI) or 4′,6-diamidino-2-phenylindole
(DAPI) staining. Flow cytometry was performed on a
FACS-Canto II (Becton Dickinson), and data was analyzed
with FlowJo Software version 8 (Treestar, Ashland, OR,
USA). Gates were set using the fluorescence minus one-
gating strategy [8]. Anti-mouse or anti-rat/hamster
CompBeads (BD) were used for compensation controls.HCT
Recipient mice (BALB/c, BALB/b, and C57Bl/6) were
myeloablatively irradiated (BALB/c, BALB/b: 8 Gy; C57Bl/
6: 9 Gy) with an electron linear accelerator (Mevatron Pri-
mus, Siemens, Germany). Bone marrow (BM) cells from
wild-type (WT) C57Bl/6 donor mice were flushed from
femur and tibia bones with phosphate-buffered saline
(PBS; PAN, Aidenbach, Germany). T cells were isolated
from spleens of luc+ C57Bl/6-L2G85 donor mice and red
blood cells were lysed. Splenic CD3+ single cell suspensions
were enriched using the Dynal Mouse T cell Negative Iso-
lation Kit (Invitrogen, Darmstadt, Germany) according to
the manufacturer’s protocol. Cell purity of the CD3+ was
confirmed by post-enrichment fluorescence-activated cell
sorting (FACS) analysis (>90%) For hematopoietic reconsti-
tution, all recipient mice were injected intravenously with
5 × 106 C57Bl/6 WT BM cells. To induce aGVHD, BALB/
c recipients (MHC major mismatch model) and syngeneic
C57Bl/6 recipients were coinjected intravenously with
1.2 × 106 enriched CD3+/luc+ and 5 × 106 BM cells, while
BALB/b recipients (miHAg mismatch model) were
coinjected intravenously with 5 × 106 CD3+/luc+ T cells
and 5 × 106 BM cells within 3 h after irradiation.
Transplanted mice were monitored daily for survival,
weight change, and clinical GVHD symptoms according to
Cooke et al. [9].
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For in vivo studies, rapamycin (Wyeth, Reading, UK)
was dissolved in carboxymethylcellulose sodium salt
(C-5013; Sigma-Aldrich, Munich, Germany) and polysor-
bate 80 (P-8074, Sigma-Aldrich) to a final concentration
of 1.5 mg/kg body weight (BW) [10] and injected intraper-
itoneally daily from day +6 to day +15 in a final volume of
100 μL.
In vivo bioluminescence imaging
Mice were anesthetized and coinjected intraperitoneally
with 80 mg/kg BW ketamine (Pfizer, Berlin, Germany)
and 16 mg/kg BW xylazine (CP Pharma, Burgdorf,
Germany) together with D-luciferin (Biosynth AG, Staad,
Switzerland) at a dose of 150 μg/g BW. Three or six
mice per group per day were imaged for analysis. Images
were captured as previously described [5,7] using an
IVIS Spectrum charge-coupled device (CCD) imaging
system (Caliper-Xenogen, Alameda, CA, USA). Imaging
data were analyzed and quantified with Living Image
Software 3.1 (Caliper-Xenogen).
Peripheral blood samples
Mice were bled daily (three mice per group) via the tail
vein and erythrocytes were lysed for FACS analysis. In
addition, 25 μL PB from each mouse was added to 100 μL
PBS/EDTA (1 mM) for white blood cell counts using a
Sysmex XT-2000i (Horgen, Switzerland).
Immunofluorescence staining and immunohistochemistry
Organs were embedded in optimal cutting temperature
(OCT) compound (Sakura, Zoeterwoude, The Netherlands)
and cut into 5-μm thick sections. Slides were kept at -20°C
until staining. After air drying and acetone fixation
(10 minutes at room temperature), sections were incu-
bated with blocking solution for 15 minutes (PBS + 1%
fetal calf serum (FCS)) prior to staining with the follow-
ing antibodies for 1 h: CD8α-Alexa488 (clone 53-6.7,
Biolegend), CD90.1-APC (clone HIS51, eBioscience),
CD4-biotin (clone RM 4-5, Biolegend), all diluted 1:100 in
PBS. Streptavidin-Alexa 546 (1:200 in PBS) was used as
secondary antibody for 30 minutes. Nuclei were stained
with Hoechst for 3 minutes, diluted 1:1,000 in PBS. Wash-
ing steps after antibody incubation and Hoechst staining
were performed in 1 × PBS (three times, 2 minutes each).
Fluorescence microscopic evaluation was performed on
a Carl Zeiss AxioImager Z1. For immunohistochemis-
try, air-dried slides were incubated with 1% H2O2 for
10 minutes before blocking with avidin-biotin (Avidin/
Biotin Blocking Kit, Vector, Linaris GmBH, Wertheim,
Germany) for 15 minutes each, followed by a 15-minute
block with 1% FCS. CD90.1-biotin antibody conjugate
(clone HIS51) was used for donor T cell staining for 1 hfollowed by the ABC method (Vector) according to the
manufacturer’s protocol.
Histologic evaluation
For histological analysis organs were fixed in PBS
containing 4% paraformaldehyde (PFA) (Roth, Karlsruhe,
Germany). Representative PFA fixed samples of GIT, liver
and skin of each group were embedded in paraffin, cut
into 3-μm thick sections, and stained with hematoxylin
and eosin (H&E). GVHD scoring was performed
according to Lerner et al. [11] based on tissue damage.
The scoring system categorized 0 as normal, 1 for mild, 2
for moderate, and 3 for severe tissue damage caused by
donor T cells. All slides were examined by an experienced
unbiased pathologist (SS).
Statistical analyses
Statistical analysis was performed with the non-
parametric Mann-Whitney test using GraphPad InStat 3
software (GraphPad, La Jolla, CA, USA) where appropri-
ate. Measurements are expressed as the mean ± standard
error of mean (SEM). Analysis was performed using
GraphPad Prism 5 software. Data reaching statistical sig-
nificance (P ≤0.05) is indicated with an asterisk (*).
Results and discussion
Understanding the precise timing of T cell engraftment
and cell migration patterns is necessary to further inves-
tigate the phenotypic and functional changes within the
lymphocyte population in order to develop a predictive
test to identify patients at high risk for aGVHD. To
study the dynamic pathophysiologic events leading to
the initiation of aGVHD we first compared survival,
weight change, and clinical aGVHD scoring in a clinic-
ally relevant model of miHAg mismatch allo-HCT (B6,
H-2b > BALB/b, H-2b) to a well-defined MHC major
mismatched aGVHD model (B6, H-2b > BALB/c, H-2d)
[5]. Initially, all miHAg mismatched recipients lost
and regained weight similar to syngeneic control mice
(Figure 1A) and did not display any clinical signs of
aGVHD within the first 2 weeks after allo-HCT (Figure 1B).
By day +15, miHAg mismatched BALB/b recipients started
to lose weight again and by day +21 mice presented the
first signs of diarrhea followed by ruffled fur and hunch-
back. However, most animals survived until the end of
the experiments at day +30 (Figure 1C). All MHC major
mismatched BALB/c recipients developed signs of a
hyperacute form of GVHD (weight loss, ruffled fur, diar-
rhea, hunched posture, and lethargy) and most animals
succumbed between day +6 and day +14 after HCT
(Figure 1A). Transfer of BM cells alone rescued all recipi-
ents from myeloablative irradiation except for one BM
control mouse that likely did not engraft (Figure 1C). Syn-
geneic albino B6 recipients (H-2b) did not develop any
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Figure 1 Differences in disease onset, survival, and clinical score between the acute minor histocompatibility antigen (miHAg)
mismatched and the hyperacute major histocompatibility complex (MHC) fully mismatched graft-versus-host disease (GVHD) models.
Myeloablatively conditioned recipients were transplanted as described or left untreated and monitored for weight change, clinical GVHD
symptoms, and survival daily after hematopoietic cell transplantation (HCT). (A) Weight change is displayed relative to day 0 of HCT. Graphs show
summarized data from two independent experiments for MHC major mismatched BALB/c mice (◯, left panel) and miHAg mismatch BALB/b
recipients (■, right panel) separately. In both panels a syngeneic control (▼) and a bone marrow control (△) were added. Error bars display
means plus or minus SEM. (B) Clinical GVHD scoring rapidly increased in symptoms in the MHC major mismatch model (●, left panel). In the
miHAg mismatch group (●, right panel) symptoms continuously increased compared to syngeneic controls (▽). (C) MHC major mismatch
recipients (◯, left panel) developed hyperacute GVHD and most animals died within 14 days after HCT. In contrast, BALB/b recipients (miHAg
mismatch, ■, right panel) mostly survived until day +30. Mice that received lethal irradiation without subsequent HCT died from the
consequences of myeloablation (×). In both panels a syngeneic control (▼) and a bone marrow control (△) were added. Graphs show
summarized data from two independent experiments for MHC major mismatch recipients (◯, left panel) and miHAg mismatch recipients
(■, right panel) separately.
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weight, and survived until the end of the experiments
(Figure 1A,C). Daily in vivo BLI measurements con-
firmed the same spatiotemporal shift of aGVHD initi-
ation to effector phase in both allogeneic models but a
diverging signal increase after miHAg mismatch allo-
HCT. These early events in aGVHD initiation are in ac-
cordance with a seminal study by Korngold and colleges
[6]. In contrast, in syngeneic HCT recipients, homeostatic
T cell proliferation led to a moderate whole body as well
as single organ signal increase compared to allogeneic re-
cipients (see Additional file 1A,B).Next, we closely monitored donor T cell migration
patterns in the clinically relevant miHAg mismatch
model to address whether it is possible to detect
alloreactive donor T cells in the PB early after allo-HCT.
Therefore, we analyzed PB samples of transplanted mice
daily by multiparameter flow cytometry (Figure 2A). By
employing the well-established MHC major mismatch
model of hyperacute GVHD we detected donor T cell
mobilization from SLOs to the PB as early as day +4
after allo-HCT. Donor CD4+ and CD8+ T cell frequen-
cies peaked between day +6 and +8 and decreased until
mice succumbed to aGVHD (Figure 2A, left panel).
C
MHC major
mismatch
MiHAg
mismatch
Syngeneic 
control
MHC major
mismatch
MiHAg
mismatch
Syngeneic 
control
d+6
d+11
d+3
α4β7 integrin
CD
8a
lp
ha
P-selectin ligand
23.8
71.4
13.5
85.2
26.1
69.6
3.94
48.5
11.5
83.2
36.2
52.2
15.7
39.9
16.6
53
71.8
22.3
12.2
56.9
17.6
56.5
71.8
23.3
20.8
24.4
60.1
20.4
43.7
26.7
71.5
17.9
1.82
46.1
2.05
4.1
4.35
7.25
17.7
13.2
9.77
16.2
3.88
0.97
45.1
9.69
5.83
13.6
2.38
4.76
0.82
1.23
4.35
0
21.5
22.9
11.9
18.5
3.88
1.94
21.8
7.74
6.04
4.43
*
* Death due to acute GVHD
*
0 5 10 15 20 25
0
1
2
3
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
0 5 10 15 20 25
0
1
2
3
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
Syngeneic control
A
MiHAg mismatch
0 5 10 15
0
1
2
3
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
MHC major mismatch
CD4+ donor T cells
CD8+ donor T cells
B
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.2
0.4
0.6
0.8
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.5
1.0
1.5
2.0
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
CD4+ α4β7+ CD8+ α4β7+
CD8+ P-selectin Ligand+CD4+ P-selectin Ligand+
MHC major mismatch
MiHAg mismatch
Syngeneic Control
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.5
1.0
1.5
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.3
0.6
0.9
1.2
1.5
Days post HCT
Ce
lls
 
/ m
l x
 
10
5
*
* *
*
MHC major mismatch
MiHAg mismatch
Syngeneic Control
D
CD8+
Days post HCT
%
 T
 
c
e
lls
4 6 11 15 21 23
0
20
40
60
80
100
CD4+
Days post HCT
%
 
T 
c
e
lls
4 6 11 15 21 23
0
20
40
60
80
100
Donor
Host
Figure 2 Migrating donor T cells after minor histocompatibility antigen (miHAg) mismatch allogeneic hematopoietic cell
transplantation (allo-HCT) can be clearly detected in the peripheral blood (PB) for at least 2 weeks before onset of acute graft-versus-
host disease (aGVHD). (A) Absolute PB T cell counts for donor CD4+ (◯) and CD8+ (■) T cells after major histocompatibility complex (MHC)
mismatch (left panel), miHAg mismatch (middle panel), and syngeneic HCT (right panel) are shown. Three mice per day per group were analyzed
(n = 15 per group). In the MHC major mismatch model, only surviving animals could be bled at later timepoints. One experiment out of three is
shown. Error bars display means plus or minus SEM. (B) T cell chimerism analysis on indicated timepoints after miHAg mismatch allo-HCT
revealed that after day +6 more than 90% of PB CD8+ and CD4+ T cells were of donor T cell origin. Of note, the detection of CD90.1+ T cells only
included transferred donor T cells but not donor bone marrow (BM)-derived CD90.2+ T cells. Results for CD8+ and CD4+ T cells of one
representative experiment are shown, separately (n = 3). (C) Representative flow cytometry plots display α4β7 integrin and P-selectin ligand
expression on donor T cells at indicated timepoints in allogeneic and syngeneic recipients. Numbers in each quadrant represent percentages of
all donor T cells. (D) Daily flow cytometry analyses revealed high numbers of cells in the PB expressing α4β7 integrin as well as P-selectin ligand
in the miHAg model (■) in comparison to the expression in syngeneic recipients (▽) which stayed constantly low. Donor T cells in the MHC
major mismatch model (◯) also strongly upregulated those receptors before mice died of aGVHD. Three mice per day per group were analyzed
(n = 15). Graphs show results from one representative experiment out of three. Error bars display means plus or minus SEM. *P ≤0.05.
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bilized to the PB by day +4, but in contrast to the
hyperacute model, elevated numbers of migrating donor
CD4+ and CD8+ T cells remained readily detectable
throughout a period of 12 days before cell numbers de-
clined and mice started to show first signs of aGVHD
(by day +21) (Figure 2A, middle panel). T cell chimerism
analysis after miHAg mismatch allo-HCT revealed that
after day +6 more than 90% of PB CD8+ and CD4+ T cells
were of donor T cell origin (Figure 2B). Of note, the detec-
tion of CD90.1+ T cells only included transferred donor T
cells but not donor bone marrow derived CD90.2+ T cells.
This explains why after day +15 CD90.1+ donor T cells ap-
parently decline. However, this cannot be ascribed to an
increase of host type T cells but rather to an increase of
donor bone marrow CD90.2+ T cells that could not be
detected by our type of chimerism analysis (Figure 2B). In
syngeneic recipients donor T cell numbers slowly butconstantly increased suggesting homeostatic T cell recon-
stitution of the immune system (Figure 2A, right panel).
Histopathological analyses of aGVHD target organs
confirmed the donor T cell infiltration in these organs.
By day +6 after MHC major mismatch allo-HCT allogen-
eic T cells markedly infiltrated target organs resulting in
massive tissue damage. In contrast, miHAg mismatch
allo-HCT recipients displayed low intestinal T cell infiltra-
tion and only mild histopathological damage on day +6.
However, by day +21, donor T cells massively infiltrated
small and large bowel of miHAg mismatch allo-HCT re-
cipients that by this time displayed the first clinical signs
of aGVHD. The tissues of syngeneic controls displayed
only mild T cell infiltrates and no tissue damage at this
time (see Additional file 2A,B). As aGVHD target organ
infiltration depends on the appropriate cellular homing re-
ceptors [3] we considered whether alloreactive T cells
could be more precisely characterized by the expression of
Figure 3 Schematic summary of events in the minor
histocompatibility antigen (miHAg) mismatch model early after
allogeneic hematopoietic cell transplantation (allo-HCT). Donor
T cell migration patterns open an at least 2-week-long diagnostic
window prior to clinical apparent acute graft-versus-host disease
(aGVHD) onset. Color bar displays days after allo-HCT. PB,
peripheral blood.
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implicated in intestinal and skin aGVHD manifestation,
respectively [12,13]. Therefore, we examined the dynamic
changes in their expression daily after HCT to test a pos-
sible correlation between their upregulation and the iden-
tified phase of massive cell migration (Figure 2C,D). Until
day +3, only few donor T cells circulated in the PB in all
three models and these cells were mostly negative for the
receptors tested. On day +6, donor T cells of the MHC
major mismatch model upregulated α4β7 integrin and
P-selectin ligand compared to a minor upregulation of
those receptors after miHAg allo-HCT. Importantly, in
the latter model upregulation of α4β7 integrin and P-
selectin ligand peaked at day +11 (45% α4β7+ CD8+ and
22% P-lig+ CD8+ donor T cells, Figure 2D). After day +11,
numbers of cells expressing these homing receptors slowly
declined correlating with a drop in absolute cell numbers.
In contrast, donor T cells in syngeneic transplanted mice
expressed only low levels of α4β7 integrin and P-selectin
ligand over time.
In line with our results, two clinical retrospective
studies indicate a correlation between homing receptor
upregulation and the subsequent development of aGVHD
symptoms. Chen and colleagues found at least tenfold
upregulation of α4β7 integrin on naïve as well as memory
T cell subsets before the onset of clinically apparent intes-
tinal GVHD compared to cutaneous or no aGVHD in a
case-controlled study including 59 patients [14]. Another
study with 33 patients found an association of cutaneous
lymphocyte antigen (CLA, a P-selectin glycoprotein
ligand-1)-upregulation on PB T cells and the onset of se-
vere aGVHD [15]. Furthermore, in a recent clinical study
Chen et al. could correlate the detection of α4β7+ memory
T cells with the appearance of intestinal aGVHD in pa-
tients [16]. However, these studies did not address how
soon before aGVHD onset and for how long these T cell
surface receptors could be detected.
Different functional studies in murine models across
major or minor MHC mismatches confirmed that α4β7
or ß7 negative donor T cells cause less aGVHD morbid-
ity and mortality compared to WT T cells mainly due to
reduced homing to the intestinal tract while still
exhibiting the GVT effect [12,17]. Likewise, ameliorated
aGVHD was observed in P-selectin-deficient mice,
which underscores the importance of the interaction be-
tween P-selectin and its ligands that are highly expressed
on migrating effector T cells [13]. In our experiments we
also found significantly higher α4β7 integrin and P-
selectin ligand expression on migrating allogeneic T cells
than in syngeneic controls. The expression of these mol-
ecules on PB donor T cells correlates with the identified
cell migration phase and strongly associates with
aGVHD induction in allo-HCT suggesting their potential
usefulness as predictive markers. Recently, researchefforts have focused on the identification of reliable pre-
dictive markers to identify patients at risk before
aGVHD onset with some potential biomarkers being in-
vestigated thoroughly [18,19]. Different combinations of
these biomarkers have been used to predict treatment
response and survival of aGVHD patients, but a predict-
ive marker panel to reliably identify patients at risk for
aGVHD is still lacking.
Figure 3 summarizes the dynamic events of aGVHD
pathophysiology after miHAg mismatch allo-HCT. The
described donor T cell migration phase with the cells be-
ing highly positive for α4β7 integrin and P-selectin lig-
and opens a potential diagnostic window for a timely
therapeutic intervention prior to the onset of clinically
apparent aGVHD, which did not develop before day +21
in this model.
Therefore, we asked whether this time frame from the
first detection of alloreactive T cells suffices to effectively
prevent aGVHD onset. Subsequently, we started to treat
mice with rapamycin [20,21] as soon as we could detect
alloreactive T cells in the PB (day +6) (Figure 4A). A
total of 10 days of rapamycin administration strongly re-
duced the total body BLI signal intensity of treated mice
compared with vehicle controls. By day +11, treated
mice already showed much less overall body signal pre-
dominantly originating from the spleen, skin, and BM
compartment. Abdominal signals were very low com-
pared with the controls. Immunofluorescence stainings
of donor T cell infiltrates in aGVHD target organs con-
firmed reduced CD90.1+ donor T cells in rapamycin-
treated mice compared to controls on day +11 after
miHAg mismatch allo-HCT (see Additional file 3A-D).
Quantification of BLI images revealed a significant
reduction of total body signal intensities by day +11 and
day +15 after allo-HCT (Figure 4B). Treated mice
showed a 7-fold lower signal by day +11 and a 13-fold
lower signal by day +15 compared with vehicle controls.
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Figure 4 Targeted rapamycin treatment starting at the first detection of peripheral blood (PB) alloreactive T cells prevents lethal acute
graft-versus-host disease (aGVHD). (A) Treatment was started as soon as alloreactive T cells could be identified in the PB based on their
surface receptor profile. Scheme indicates time course of repeated rapamycin injections. Ventral and lateral bioluminescence imaging (BLI) images
of representative mice per group (n = 5) are displayed. On days +15 and +21, signal thresholds were increased to resolve the predominant organ
distribution of donor T cells. (B) BLI signals significantly decreased on days +11 and +15 in treated mice compared to vehicle controls (n = 5).
Error bars display means plus or minus SEM. *P ≤0.05. (C) All rapamycin-treated mice (■) showed limited signs of aGVHD (left panel) on day +21
but rapidly and fully recovered. All rapamycin-treated mice survived (right panel) until the end of the experiment (day +100). In contrast, vehicle
controls (◯) developed increasing signs of aGVHD starting by day +21 and 60% succumbed to aGVHD up to day +100. Mice that received lethal
irradiation without subsequent hematopoietic cell transplantation (HCT) died of the consequences of myeloablation (×). Animals that received
transplants of bone marrow alone did not show any clinical signs of aGVHD and survived (△). One experiment out of two is shown (n = 5).
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treated group slightly increased but the benefit of the
treatment remained apparent with a fourfold lower BLI
signal compared to control mice. Importantly, rapamycin
treatment resulted in the recovery from already visible
aGVHD symptoms occurring by day +21 (Figure 4C)
that constantly improved thereafter. All mice treated in
a timely fashion with rapamycin survived (Figure 4C).
We propose that the identified migration phase of
alloreactive T cells may serve as a potential diagnostic
window for early and timely targeted therapeutic inter-
ventions. In addition to the described surface markers,
α4β7 integrin and P-selectin ligand, combinations with
other markers appear attractive. Further investigations of
suitable surface receptor combinations to precisely iden-
tify alloreactive PB T cells could be complemented by
detecting polypeptides in the urine of patients as early
indicators for aGVHD. Kaiser et al. identified two pep-
tides of the leukotriene A4 hydrolase and of serum albu-
min as possible biomarkers [22]. Furthermore, tumor
necrosis factor receptor 1 (TNFR1), interleukin 2 recep-
tor alpha (IL-2Ra), IL-8, and hepatocyte growth factor
(HGF) as plasma biomarkers relevant for aGVHDeffectively discriminated between patients with and with-
out aGVHD [23] and elafin functioned as a biomarker for
skin aGVHD patients [24]. Different combinations of
these biomarkers have been used to predict treatment re-
sponse and survival of aGVHD patients [18,19]. We envi-
sion combining the described homing receptor panel with
these biomarkers in order to develop a reliable predictive
test to identify patients at risk before disease onset.
Encouraging for the clinical allo-HCT setting, the di-
rected, preemptive rapamycin treatment starting imme-
diately at the first detection of alloreactive donor T
cells significantly improved aGVHD symptoms and
granted survival in all miHAg allo-HCT recipients.
Similarly, preemptive treatment with other immuno-
modulators and, particularly, drugs altering T cell traf-
ficking [25] appear highly attractive, but may exert their
biggest benefit if individuals at high risk for aGVHD
can be identified in a timely manner before the first
clinical symptoms appear.
Conclusions
In the present study, we demonstrate in a clinically rele-
vant miHAg allo-HCT mouse model that it is feasible to
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http://www.biomedcentral.com/1741-7015/11/134detect migrating alloreactive donor T cells for an ex-
tended time period of 2 weeks and, importantly, before
aGVHD symptoms become apparent. As the prediction
of aGVHD is highly relevant to the clinical outcome, it
may be beneficial to closely monitor the kinetics of T
cell engraftment, expansion, and homing receptor ex-
pression in allo-HCT patients. Our preclinical findings
may have implications for the development of a predict-
ive blood test identifying patients at risk for aGVHD and
thereby giving physicians the chance for a timely and
targeted therapeutic intervention.Additional files
Additional file 1: Initial donor T cell proliferation and migration after
allogeneic hematopoietic cell transplantation (allo-HCT) follows the
same spatiotemporal pattern but differs in bioluminescence imaging
(BLI) signal increase in the major histocompatibility complex (MHC)
versus the minor histocompatibility antigen (miHAg) mismatched
mouse model. (A) Luc+ donor T cells proliferate in secondary lymphoid
organs (SLOs) until day +3 in both allogeneic models. They show the
same spatiotemporal shift from acute graft-versus-host disease (aGVHD)
initiation to effector phase but in the miHAg mismatch model (middle
panel) signals increase less intensely compared to the MHC major
mismatch model (upper panel) during the first 7 days followed by a
strong increase in whole body signal intensity from day +8 on. In
syngeneic transplanted albino B6 mice (lower panel) donor T cells initially
also home to SLOs but as well to the thymus and bone marrow (BM)
and not to the skin. One representative mouse per group (n = 6) is
shown. (B) Quantification of dynamic total body and single organ BLI
signal changes. Photon emissions per second per whole animal and
average photon radiation for representative target organs are displayed.
Total body BLI signals increase dramatically in mice with aGVHD in both
allogeneic models, MHC major (●) and miHAg (■) mismatched groups,
but only moderately in syngeneic (▼) transplanted mice. Overall
gastrointestinal tract (GIT) and skin signal intensities of the MHC major
mismatched mice increase much stronger than in the miHAg
mismatched model before those mice die of aGVHD. Error bars display
means plus or minus SEM (n = 6).
Additional file 2: Alloreactive donor T cell infiltrates cause severe
tissue damage in acute graft-versus-host disease (aGVHD) target
organs. Immunohistochemical stainings of representative small (A) and
large (B) bowel samples on day +6 after hematopoietic cell
transplantation (HCT) showed a massive infiltration by donor T cells in
the major histocompatibility complex (MHC) mismatch model as
compared to minor histocompatibility antigen (miHAg) mismatch and
syngeneic recipients’ tissues. By day +21, donor T cells infiltrated small
and large bowel of the miHAg mismatch transplanted mice and were
more abundant than in the organs of syngeneic recipients.
Immunofluorescence microscopy of target tissues on day +21 after HCT
in the miHAg mismatched compared to syngeneic recipients confirmed
these results ((A) and (B), lower panels). CD4+ (Streptavidin-Alexa546,
displayed in blue) as well as CD8+ (Alexa-488, displayed in green) donor
T cells (CD90.1-APC, displayed in red) massively infiltrated small and large
bowel of miHAg mismatch recipients. Double-positive cells appear in
purple (CD90.1+ CD4+) and yellow (CD90.1+ CD8+), respectively. In
syngeneic recipients, double-positive donor T cells also migrated into
these organs, but unlike in allogeneic recipients did not cause tissue
damage. (C) Quantification of infiltrating donor T cells showed that more
cells infiltrated the small and large bowel in allogeneic than in syngeneic
recipients on day +6 (left panel) as well as on day +21 (right panel) after
allo-HCT. Similar results were seen in liver and skin. One of three
independent experiments is shown (n = 3). Error bars display means plus
or minus SEM. HPF, high power field.Additional file 3: There is less donor T cell infiltration in acute
graft-versus-host disease (aGVHD) target organs in rapamycin-
treated mice than in aGVHD control animals. On day +11 after minor
histocompatibility antigen (miHAg) mismatch allogeneic hematopoietic
cell transplantation (allo-HCT), donor T cells (CD90.1-APC, displayed in
green) massively infiltrated small (A) and large bowel (B) in aGVHD and
vehicle control animals whereas the gastrointestinal tract of rapamycin-
treated mice showed less donor cell infiltration. Similar results were seen
in liver (C) and skin (D) samples. Images show immunofluorescence
stainings of one representative mouse per group (n = 5). Cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI) (displayed in white).
Images were taken with 40 ×magnification. LB, large bowel; SB, small
bowel.
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